RT @End_myeloma
Now that horse is out of the barn... a few important points about KARMMA-3 #mmsm @paurotero @NBahlis @MyelomaTeacher #myeloma

1/X - First randomized phase 3 trial to show clinical benefit for Car-T cell therapy in MM. That is HUGE. https://twitter.com/RahulBanerjeeMD/status/1611391189835730947

RT @AndreaAnampaG@twitter.com

Our work on the Health Disparities Experienced by Hispanic Americans with Multiple Myeloma is now at Clinical Hematology International. Thanks to
@Sarasinh@twitter.com, @inas_md@twitter.com and @HadidiSamer@twitter.com

LINK: https://link.springer.com/article/10.1007/s44228-022-00026-2

#HOFellows #Latinx #MMsm #BMTsm #myeloma #GlobOnc #MedTwitter

🐦🔗: https://twitter.com/AndreaAnampaG/status/1609926850389622784

That third chart is the one I look for every time there’s a conference. It’s easy to see only 3 red squares. It’s also terrifying to see 3 squares.
---
RT @UrviShahMD
Congratulations @kordeneha1 on presenting patient centric data from the maintenance cessation study in myeloma showing 12 month MRD negativity rate of 88% with stable trends in HRQoL @MSKCancerCenter #mmsm #ASH22 #ASHkudos
https://twitter.com/UrviShahMD/status/1602440627534405632

That third chart is the one I look for every time there’s a conference. It’s easy to see only 3 red squares. It’s also terrifying to see 3 squares.
---
RT @UrviShahMD
Congratulations @kordeneha1 on presenting patient centric data from the maintenance cessation study in myeloma showing 12 month MRD negativity rate of 88% with stable trends in HRQoL @MSKCancerCenter #mmsm #ASH22 #ASHkudos
https://twitter.com/UrviShahMD/status/1602440627534405632

RT @MidAtlanticMSG
I'm a visual person, and these schematics make me happy, not just because of their appearance, but the amount of drugs available to choose from! Keep them coming! #IMFASH22 #ASH22 #myeloma #mmsm

RT @mtmdphd
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial [Sun, Dec 11, 2022] Manier et al. Abs 569 #ASH22 https://ash.confex.com/ash/2022/webprogram/Paper159933.html #mmsm #caxtx